drugset / Trial / NCT00490009
Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to obtain safety and efficacy data using Bexxar in patients with relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL).
Timeline
- Start
- 2004-09
- Primary completion
- 2010-04
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TOSITUMOMAB 131I | Monoclonal antibody | — | — |
| Background | Acetaminophen | Small molecule | 650 mg | Oral |
| Background | Diphenhydramine | Unknown | 50 mg | Oral |
| Background | Potassium Iodide (KI) | Unknown | 130 mg | Oral |